Searched for
CDMO AND CRO
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...- Stock to buy: Jefferies lists 10 reasons to buy its top CRDMO pick Sai Life SciencesJefferies has initiated coverage on Sai Life Sciences with a 'Buy' rating and a Rs 1,300 target price, citing its integrated 'follow-the-mo...
- Pharmexcil drives global pharma trade through premier healthcare export summitThe 11th edition of iPHEX, India's flagship pharmaceutical export exhibition, will be held in New Delhi from September 4-6, 2025.
- China+1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman SachsIndian pharmaceutical and biotech sectors are experiencing early benefits from the global shift away from China, driven by the China+1 stra...
- ETMarkets PMS Talk: Why InCred Healthcare PMS is overweight on hospitals and diagnostics for 2025InCred healthcare portfolio offers a structural investment product that invests in 5 different baskets of businesses like Branded Generics,...
- Piramal Pharma shares zoom 8% as JM Financial sets Rs 340 targetPiramal Pharma shares rose 8.3% after JM Financial initiated coverage with a target price of Rs 340, citing strong growth potential driven ...
- Why Mayuresh Joshi prefers Syngene to Biocon, Paradeep Phosphates to UPLMayuresh Joshi, Head Equity, Marketsmith India, shared his insights on the performance of various companies. He noted that while UPL's numb...
- ETMarkets Smart Talk: Sachin Shah on India's role in 'China +1' and 'Europe +1' strategies in global supply chainsGlobal purchasing managers have been seeking to de-risk procurement from China for many years. They have been working on this, but post-COV...
- Quality outperforming value; set sights on 3 sectors: Aashish SomaiyaaAashish Somaiyaa, CEO of WhiteOak Capital AMC, discusses the recent market trends in IT, pharma, and consumer sectors. He highlights the se...
- Bino Pathiparampil expects positive momentum in pharma sector; has 3 top picksBino Pathiparampil of Elara Capital discussed the strong Q1 FY25 performance in the pharma sector. Companies like Lupin and Dr Reddy's rece...
- Foram Parekh on what to bet on in pharma packForam Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about L...
- India's healthcare care innovation market to double to $60 billion by FY28, says new reportThe report outlines the opportunity in healthcare innovation where companies increasingly leverage emerging technologies to add innovation ...
- Why Vikas Khemani has a bullish view in short, medium & long term“We are very, very positive on the CDMO and CRO space within pharma, which we think is a very structural trend over the next 5 to 10 to 15 ...
- Aurigene Pharmaceutical Services to set up USD 40 mn facility in HyderabadAurigene Pharmaceutical Services Ltd will establish its state-of-the-art biomanufacturing facility at an investment of USD 40 million here,...
- CRO market still very much untapped in India: Cyndrella CarvalhoIndian CROs and CDMOs are attracting a lot of attention as companies, such as Syngene, Suven, and Divis, create long-term relationships wit...
- PI Industries stock zooms 13%, hits two-month high on pharma acquisitionsOn Thursday, PI Industries announced twin acquisitions into pharma API and CDMO space, stating that it is committed to building a different...
- CRAMS could be new wealth creators in pharma spaceMore and more pharma cos are finding it profitable to outsource all aspects from R&D to commercialisation to trusted partners in low-cost c...
- Why investors should focus on long-term structural stories rather than recovery playsThe interesting theme we invested in was IT ER&D services (IT embedded services) as the trend of ever increasing application of electronics...
- Carlyle picks up 20% stake in Piramal pharma biz for $490 mnThe 20% stake sale values Piramal’s pharma business at Rs 20,000 crore.
- Buy Suven Life Sciences, target Rs 270: Emkay Global Financial ServicesBuy Suven Life Sciences Ltd. at a price target of Rs 270.0 .
Load More
